Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe And Hitachi Establish Therapeutic Robot Center In Japan

This article was originally published in PharmAsia News

Executive Summary

Japanese medical device makers Hitachi and Shimadzu, mechatronics giant Yaskawa Denki and drug company Mitsubishi Tanabe Pharma July 9 jointly established a medical robot center in Fukuoka. Based inside Kyushu University Hospital, the center will employ advanced technology to develop endoscopic robots able to operate inside the human body. The Japanese government will provide ¥1.2 billion to encourage innovation in therapeutic robot technology. The center also plans to develop devices to conduct remote surgeries and chemical compounds to detect tumors with diameters of 1 millimeter. (Click here for more - Japanese language

You may also be interested in...



Biden Regulatory Freeze May Pause Sunset Rule, Medicare Rebate, Medicaid Line Extension Regs

Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.

US FDA Still “Actively” Drafting Proposed Licensing Rule For Wholesalers and 3PLs

Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.

P&G Boosts Guidance Again Despite Dipping 'Consumption Levels' Expected Through June

On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel